Yüklüyor......

Differential binding patterns of monoclonal antibody 2C4 to the ErbB3–p185(her2/neu) and the EGFR–p185(her2/neu) complexes

2C4 (Pertuzumab, Omnitarg) is a monoclonal antibody targeting p185(her2/neu), which is overexpressed in 30% of invasive breast cancer. 2C4 is currently in phase II clinical trials for several types of cancers. This antibody has been reported to disrupt the association between p185(her2/neu) and ErbB...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Cai, Z, Zhang, G, Zhou, Z, Bembas, K, Drebin, JA, Greene, MI, Zhang, H
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2008
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2819401/
https://ncbi.nlm.nih.gov/pubmed/18264138
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/onc.2008.13
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!